Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab for Prevention of GVHD After Allogeneic Stem Cell Transplantation
NCT07349771Phase 2Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of axatilimab in graft-versus-host disease (GVHD), sponsored by Mayo Clinic. Planned start Jun 2026; status: withdrawn.
02
Drugs
axatilimab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07349771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07349771.